Randomized, Placebo-Controlled Phase 3 Trial Protocol Assessing the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Acromegaly

Octreosphere (octreotide extended release) - Xbrane

Somatuline Depot (lanreotide prolonged-release subcutaneous) - Ipsen, Teijin

Somavert (pegvisomant) - Pfizer

Signifor (pasireotide) - Recordati

octreotide chloride FluidCrystal Injection depot (CAM2029) - Novartis

Sandostatin LAR Depot (octreotide acetate) - Novartis

https://www.abstractsonline.com/pp8/#!/10774/presentation/5813

Diego Ferone; PhD1; Pamela Freda; MD2; Laurence Katznelson; MD3; Federico Gatto; MD1; Aleksandra Gilis-Januszewska; MD; PhD4; Murray B. Gordon; MD5; Pinar Kadioglu; MD6; Pietro Maffei; MD7; Jochen R. Seufert; MD; PhD; FRCPE8; Julie Silverstein; MD9; Joanna L. Spencer-Segal; MD; PhD10; Maria Harrie; PhD11; Agneta Svedberg; MSc; MBA11; Fredrik Tiberg; PhD11

May 11, 2023